Peel Therapeutics, CEO and Co-Founder
Peel Therapeutics; Huntsman Cancer Institute, University of Utah
Dr. Schiffman is a Professor of Pediatric Hematology-Oncology and Investigator at Huntsman Cancer Institute at the University of Utah. Dr. Schiffman holds the Helen Clise Presidential Endowed Chair in Li-Fraumeni Syndrome Research. Dr. Schiffman is also the CEO and Co-founder of PEEL Therapeutics, a USA-Israeli biotech that engineers evolutionary biology to develop new medicines for cancer and inflammation (“PEEL” = Hebrew word for elephant). Dr. Schiffman has published over 175 peer review articles and book chapters, including topics on pediatric cancer genomics, hereditary cancer risk, and comparative oncology. He has held multiple NIH grants throughout his career, including Ewing sarcoma R01 and Leiomyosarcoma (LMS) SPORE grant. Dr. Schiffman graduated from the Brown University School of Medicine in 2000, followed by clinical training in Pediatrics and Pediatric Hematology-Oncology at Stanford University from 2000-2008. Dr. Schiffman’s academic research and now biotech efforts focus on cancer risk in children and studying animals that naturally are protected from cancer, like elephants. Dr. Schiffman is dedicated to improving sarcoma outcomes through novel approaches to diagnosis, treatment, and prevention.
